fypryst 402 mg, soluţie spot-on pentru câini
krka dd novo mesto, slovenia - fipronil - soluţie spot on
fypryst 268 mg, soluţie spot-on pentru câini
krka dd novo mesto, slovenia - fipronil - soluţie spot on
fypryst 134 mg, soluţie spot-on pentru câini
krka dd novo mesto, slovenia - fipronil - soluţie spot on
fypryst 67mg, soluţie spot-on pentru câini
krka dd novo mesto, slovenia - fipronil - soluţie spot on
fypryst combo 50/60mg, soluţie spot-on pentru pisici şi dihori domestici
krka dd novo mesto, slovenia - fipronil, - soluţie spot on
alutard sq venin de albina (cutie pt. initiere a dozei)
alk-abello a/s - spania - extract alergenic standardizat din venin despre albina - susp. inj. - 100sq-u/ml-100000sq-u/ml - alergeni alergeni - extracte
alutard sq venin de albina 100000 sq-u/ml
alk-abello a/s - spania - extract alergenic standardizat din venin despre albina - susp. inj. - 100000sq-u/ml - alergeni alergeni - extracte
albiomin 200g/l
biotest pharma gmbh - germania - albuminum umane - sol. perf. - 200g/l - sange si substituenti de sange substituenti de sange si fractiuni proteice plasmatice
albiomin 50g/l
biotest pharma gmbh - germania - albuminum umane - sol. perf. - 50g/l - sange si substituenti de sange substituenti de sange si fractiuni proteice plasmatice
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.